Ironwood Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Good morning, everyone. My name is Balaji Prasad. I'm the Senior Analyst for the Spec Pharma coverage for Barclays.
So kick starting the day for the Barclays Annual Global Healthcare Conference, we have the pleasure of having the management team from Ironwood with us. So, Tom McCourt, CEO; and Greg Martini, Vice President, Strategic Finance and Investor Relations.
Tom and Greg, thank you so much for joining us today. So, we have around 25 minutes. In terms of the organization, why don't we start with just couple of recaps, you reported a few weeks ago? Maybe a couple of recaps and then we can go into Q&A.
Sure. So as you know, Ironwood is a GI-focused health care company with a lead asset, LINZESS, which is now considered a blockbuster in terms of US net sales. We have really 3 strategic imperatives. First of all, of course, maximize LINZESS. Second, how do we continue to advance our GI portfolio; and 3
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
